Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Lifecore Biomedical (NASDAQ:LFCR) released its quarterly earnings results on Wednesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.19), FiscalAI reports. The firm had revenue of $23.19 million for the quarter, compared to analysts’ expectations of $25.96 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance and mid‑term targets — Lifecore reiterated 2026 revenue guidance of $120–125M and adjusted EBITDA of $20.5–25M, and reiterated a goal of 12% revenue CAGR and >25% EBITDA margin by end of 2029.
• Q1 results disappointed — revenue fell 34% year‑over‑year to $23.2M, gross profit declined and the company reported a $15M net loss with adjusted EBITDA of $1M, driven by front‑loaded headwinds and timing shifts.
• Notable business development wins — signed three commercial site‑transfer/CDMO agreements (including an aesthetics onshore transfer and two programs with a U.S. biopharma customer) and expanded a late‑stage pipeline, with these transfers expected to be commercial by 2028 and represent mid‑seven‑figure opportunities each.
• Expense cuts and stronger liquidity — SG&A and R&D reduced by nearly $8M since late‑2024, fifth consecutive quarter of positive operating cash flow, and ending Q1 liquidity of ~ $38M (~$21M cash + ~$17M revolver availability).
• Operational and quality progress — ERP implementation went smoothly in January, multiple customer inspections had positive outcomes, and the company is preparing to support a planned doubling of its largest customer’s commercial demand beginning in 2027.

Lifecore Biomedical Stock Performance

NASDAQ LFCR traded down $0.20 during trading on Wednesday, reaching $4.96. 221,757 shares of the company’s stock were exchanged, compared to its average volume of 270,751. The stock has a market cap of $185.90 million, a P/E ratio of -5.06 and a beta of 1.08. The company has a 50 day moving average price of $5.29 and a two-hundred day moving average price of $6.83. Lifecore Biomedical has a 1 year low of $3.63 and a 1 year high of $8.98.

Institutional Trading of Lifecore Biomedical

A number of institutional investors have recently bought and sold shares of LFCR. Invesco Ltd. purchased a new stake in Lifecore Biomedical during the 2nd quarter worth about $3,081,000. Squarepoint Ops LLC lifted its holdings in Lifecore Biomedical by 385.9% during the 3rd quarter. Squarepoint Ops LLC now owns 150,909 shares of the company’s stock worth $1,111,000 after buying an additional 119,851 shares during the last quarter. Millennium Management LLC lifted its holdings in Lifecore Biomedical by 86.2% during the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after buying an additional 116,500 shares during the last quarter. Quinn Opportunity Partners LLC lifted its holdings in Lifecore Biomedical by 31.5% during the 4th quarter. Quinn Opportunity Partners LLC now owns 242,670 shares of the company’s stock worth $1,985,000 after buying an additional 58,189 shares during the last quarter. Finally, State Street Corp lifted its holdings in Lifecore Biomedical by 8.5% during the 4th quarter. State Street Corp now owns 585,386 shares of the company’s stock worth $4,788,000 after buying an additional 46,102 shares during the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LFCR has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Tuesday, April 21st. Barrington Research lifted their target price on Lifecore Biomedical from $5.50 to $6.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.